Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement

Hannes Hagström, Leon A. Adams, Alina M. Allen, Christopher D. Byrne, Yoosoo Chang, Henning Grønbæk, Mona Ismail, Peter Jepsen, Fasiha Kanwal, Jennifer Kramer, Jeffrey V. Lazarus, Michelle T. Long, Rohit Loomba, Philip N. Newsome, Ian A. Rowe, Seungho Ryu, Jörn M. Schattenberg, Marina Serper, Nick Sheron, Tracey G. Simon, Elliot B. Tapper, Sarah Wild, Vincent Wai‐Sun Wong, Yusuf Yilmaz, Shira Zelber‐Sagi, Fredrik Åberg – 22 January 2021

Liver Transplantation for Langerhans Cell Histiocytosis: A US Population‐Based Analysis and Systematic Review of the Literature

Ioannis A. Ziogas, Christos D. Kakos, W. Kelly Wu, Martin I. Montenovo, Lea K. Matsuoka, Sara Zarnegar‐Lumley, Sophoclis P. Alexopoulos – 22 January 2021 – Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder. Liver involvement is seen in 10.1% to 19.8% of patients with LCH and can lead to secondary sclerosing cholangitis requiring liver transplantation (LT). We describe the characteristics and outcomes of patients undergoing LT for LCH.

LiverLearning®: 2021 Webinar: To Stop or Not to Stop: The Practice of Finite Nucleos(t)ide Analog Therapy

This one-hour webinar will summarize the data that supports the finite strategy of nucleos(t)ide analog (NA) therapy in patients with chronic hepatitis B. Further discussion on how the presenter practices the strategy. In the second half of the webinar, the presenter will present data that argues against the rationale of a finite NA therapy. The presenter will elaborate on why stopping NA before loss of HBsAg cannot be recommended.

Subscribe to